文献速递青光眼

原发性小梁切除与引流管植入试验3年随访的治疗结果

Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up.
PubMed 文献 · Ophthalmology · 2019-10-09

PTVT研究为无遮蔽多中心随机临床试验,纳入242例药物无法控制且未行切口性眼手术的青光眼患者,随机接受350-mm2 Baerveldt引流管植入或丝裂霉素C(0.4 mg/ml作用2分钟)小梁切除术。3年随访时两组手术失败率无显著差异(33% vs 28%,P=0.17),小梁切除术组眼压更低且用药更少。

要点

  • 3年累积失败率引流管组33% vs 小梁切除组28%(P=0.17;HR 1.39;95%CI 0.9-2.2),无显著差异。
  • 3年时平均眼压引流管组14.0±4.2 mmHg vs 小梁切除组12.1±4.8 mmHg(P=0.008)。
  • 青光眼用药数引流管组2.1±1.4 vs 小梁切除组1.2±1.5(P<0.001)。

核心结论

  • 3年时两种手术方式的手术失败率无显著差异。
  • 在PTVT研究中,随访3年后小梁切除术联合丝裂霉素C相比引流管植入术获得更低眼压且使用更少青光眼药物。
  • 两种手术后发生导致视力丧失或需再次手术的严重并发症频率相似。

研究设计与样本

  • 无遮蔽多中心随机临床试验(PTVT研究)。
  • 纳入242例(242眼)药物无法控制且既往无切口性眼手术的青光眼患者,其中引流管组125眼、小梁切除组117眼。
  • 患者在16个临床中心入组,随机分配至350-mm2 Baerveldt青光眼引流管植入或小梁切除术联合丝裂霉素C(0.4 mg/ml作用2分钟)。

主要发现

  • 3年随访累积失败概率引流管组33% vs 小梁切除组28%(P=0.17;HR 1.39;95%CI 0.9-2.2)。
  • 3年时平均±标准差眼压引流管组14.0±4.2 mmHg vs 小梁切除组12.1±4.8 mmHg(P=0.008)。
  • 青光眼用药数引流管组2.1±1.4 vs 小梁切除组1.2±1.5(P<0.001)。
  • 需再次手术或导致Snellen视力下降2行及以上的严重并发症引流管组3例(2%)vs 小梁切除组9例(8%)(P=0.11)。

关键数值与推荐

  • 主要结局手术失败定义为眼压>21 mmHg或较基线下降<20%、眼压≤5 mmHg、因青光眼再次手术或光感视力丧失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 3-year results of the Primary Tube Versus Trabeculectomy (PTVT) Study. DESIGN: Unmasked multicenter randomized clinical trial. PARTICIPANTS: Two hundred forty-two eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 in the tube group and 117 in the trabeculectomy group. METHODS: Patients were enrolled at 16 clinical centers and were assigned randomly to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes). MAIN OUTCOME MEASURES: The primary outcome measure was the rate of surgical failure, defined as intraocular pressure (IOP) of more than 21 mmHg or reduced less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vision. Secondary outcome measures included IOP, glaucoma medical therapy, visual acuity, and surgical complications. RESULTS: The cumulative probability of failure after 3 years of follow-up was 33% in the tube group and 28% in the trabeculectomy group (P = 0.17; hazard ratio, 1.39; 95% confidence interval, 0.9-2.2). Mean ± standard deviation IOP was 14.0±4.2 mmHg in the tube group and 12.1±4.8 mmHg in the trabeculectomy group at 3 years (P = 0.008), and the number of glaucoma medications was 2.1±1.4 in the tube group and 1.2±1.5 in the trabeculectomy group (P < 0.001). Serious complications requiring reoperation or producing loss of 2 or more Snellen lines developed in 3 patients (2%) in the tube group and 9 patients (8%) in the trabeculectomy group (P = 0.11). CONCLUSIONS: There was no significant difference in the rate of surgical failure between the 2 surgical procedures at 3 years. Trabeculectomy with MMC achieved lower IOP with use of fewer glaucoma medications compared with tube shunt surgery after 3 years of follow-up in the PTVT Study. Serious complications producing vision loss or requiring reoperation occurred with similar frequency after both surgical procedures.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Gedde SJ, Feuer WJ, Lim KS, et al. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology. 2019. PMID: 31727428. doi:10.1016/j.ophtha.2019.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。